Multivariate models for overall mortality (1 − OS) and TRM in patients aged 70 years and older who received an allogeneic HCT
| Effect . | No. . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Overall mortality | ||||
| HCT-comorbidity index | ||||
| 0-2 | 479 | 1.000 | — | — |
| ≥3 | 415 | 1.269 | 1.070, 1.504 | .0061 |
| Donor type | .0046* | |||
| HLA-matched, related | 202 | 1.000 | — | — |
| HLA-mismatched, related | 67 | 1.209 | 0.848, 1.724 | .2932 |
| HLA-matched, URD < = 30 y old | 233 | 0.933 | 0.726, 1.199 | .5874 |
| HLA-matched, URD > 30 y old | 210 | 1.144 | 0.898, 1.457 | .2754 |
| HLA-matched, URD of unknown age | 19 | 0.838 | 0.425, 1.649 | .6080 |
| HLA-mismatched, URD | 67 | 1.324 | 0.945, 1.854 | .1025 |
| HLA matching unknown, URD | 45 | 1.178 | 0.782, 1.775 | .4340 |
| UCB | 51 | 1.963 | 1.372, 2.809 | .0002 |
| Conditioning intensity | ||||
| RIC/NMA | 791 | 1.000 | — | — |
| Overall mortality for patients with early/intermediate AML/MDS and chemosensitive NHL | ||||
| Sex | ||||
| Male | 359 | 1.00 | — | — |
| Female | 165 | 1.30 | 1.03-1.65 | .03 |
| Conditioning intensity | ||||
| RIC/NMA | 473 | 1.00 | — | |
| MA | 50 | 1.60 | 1.13-2.28 | .009 |
| TRM for patients with early/intermediate AML/MDS and chemosensitive NHL | ||||
| Conditioning intensity | ||||
| RIC/NMA | 473 | 1.00 | — | — |
| MA | 50 | 2.06 | 1.32-3.22 | .001 |
| Effect . | No. . | HR . | 95% CI . | P . |
|---|---|---|---|---|
| Overall mortality | ||||
| HCT-comorbidity index | ||||
| 0-2 | 479 | 1.000 | — | — |
| ≥3 | 415 | 1.269 | 1.070, 1.504 | .0061 |
| Donor type | .0046* | |||
| HLA-matched, related | 202 | 1.000 | — | — |
| HLA-mismatched, related | 67 | 1.209 | 0.848, 1.724 | .2932 |
| HLA-matched, URD < = 30 y old | 233 | 0.933 | 0.726, 1.199 | .5874 |
| HLA-matched, URD > 30 y old | 210 | 1.144 | 0.898, 1.457 | .2754 |
| HLA-matched, URD of unknown age | 19 | 0.838 | 0.425, 1.649 | .6080 |
| HLA-mismatched, URD | 67 | 1.324 | 0.945, 1.854 | .1025 |
| HLA matching unknown, URD | 45 | 1.178 | 0.782, 1.775 | .4340 |
| UCB | 51 | 1.963 | 1.372, 2.809 | .0002 |
| Conditioning intensity | ||||
| RIC/NMA | 791 | 1.000 | — | — |
| Overall mortality for patients with early/intermediate AML/MDS and chemosensitive NHL | ||||
| Sex | ||||
| Male | 359 | 1.00 | — | — |
| Female | 165 | 1.30 | 1.03-1.65 | .03 |
| Conditioning intensity | ||||
| RIC/NMA | 473 | 1.00 | — | |
| MA | 50 | 1.60 | 1.13-2.28 | .009 |
| TRM for patients with early/intermediate AML/MDS and chemosensitive NHL | ||||
| Conditioning intensity | ||||
| RIC/NMA | 473 | 1.00 | — | — |
| MA | 50 | 2.06 | 1.32-3.22 | .001 |
The first model for overall mortality in a population from 2008 to 2013 and all hematologic malignances. The second multivariate analysis includes models for overall mortality for patients with early/intermediate AML/MDS and chemosensitive NHL and TRM for a subset of patients with early and intermediate AML and MDS who received an allogenic HCT from 2008 to 2013.
MA, myeloablative; UCB, umbilical cord blood; URD, unrelated donor.
Donor type variable was tested with 7 degrees of freedom and divided the group of matched unrelated donor according to donor age divided at the median.